期刊
THERAPEUTIC ADVANCES IN HEMATOLOGY
卷 3, 期 4, 页码 199-207出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620712445329
关键词
CD20; therapeutic monoclonal antibodies; chronic lymphocytic leukemia; ofatumumab
类别
There are now many therapeutic CD20 monoclonal antibodies undergoing clinical trials for B-cell malignancy and autoimmune conditions; which is optimal for cancer therapy is not clear. The novel human IgG1 CD20 monoclonal antibody ofatumumab has shown significant activity in difficult to treat patients with chronic lymphocytic leukemia, namely those resistant or refractory to fludarabine and alemtuzumab and has now been licensed for this uncommon indication. This brief review summarizes the clinical data obtained with ofatumumab in CLL in terms of both efficacy and toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据